Recent Share Conversion at Orion Corporation
Recently, an important change took place in Orion Corporation’s share structure, marking another milestone as it continues its path as a respected player in the pharmaceutical industry.
Conversion Details
In accordance with the Articles of Association of Orion Corporation, 213,285 A shares were converted into 213,285 B shares. This conversion has been officially recorded in the Trade Register, demonstrating the company’s ongoing commitment to refining its share distribution.
Impact on Total Share Count
After this conversion, the total share count for Orion Corporation is now 141,134,278 shares. The revised structure comprises 32,974,309 A shares and a substantial 108,159,969 B shares. This change not only alters the share composition but also impacts the voting rights, which have now reached 767,646,149 votes across the company’s shares.
Company Overview
Orion Corporation has firmly established itself as a key player in the global pharmaceutical field, with a history spanning over a century. The company focuses on the development, manufacturing, and distribution of pharmaceuticals for both humans and animals, as well as active pharmaceutical ingredients. Orion’s commitment to healthcare innovation shines through its diverse portfolio that includes both proprietary and generic medicines, in addition to consumer health products. Key areas of research and development for Orion include oncology and pain management, with proprietary products designed to address cancer, neurological disorders, and respiratory conditions.
Financial Performance
In its latest financial year, Orion reported net sales of EUR 1,190 million, showcasing solid performance in a competitive environment. The company also employs about 3,600 dedicated professionals who are essential to its success and ongoing growth.
About the Leadership Team
Key members of the Orion Corporation leadership team play crucial roles in steering the company’s strategic goals and enhancing operational efficiency. Notable figures include René Lindell, the Chief Financial Officer, and Olli Huotari, Senior Vice President of Corporate Functions. Their leadership is vital for Orion's continued innovation and success amidst industry challenges.
Contact Information
For any further inquiries, individuals can contact Tuukka Hirvonen from Orion Corporation's Investor Relations team by phone at +358 10 426 2721. The company’s headquarters is situated at Orionintie 1A, FI-02200 Espoo, Finland.
Frequently Asked Questions
What prompted the conversion of A shares to B shares at Orion Corporation?
The conversion aimed to optimize share distribution and improve the capital structure, allowing for greater flexibility and efficiency in managing the company's equity.
What is the significance of the number of votes after the conversion?
After the conversion, the total number of votes increased to 767,646,149, reflecting the restructuring of shares, which can significantly influence decision-making during shareholder meetings.
How does Orion Corporation contribute to the pharmaceutical industry?
Orion Corporation makes its mark through a comprehensive portfolio of both proprietary and generic pharmaceuticals, focusing on essential areas such as oncology and pain management while providing innovative solutions to various medical challenges.
What can investors expect from Orion Corporation moving forward?
Investors can anticipate ongoing growth and resilience, as Orion Corporation stays dedicated to its mission of improving well-being through pharmaceutical innovation and maintaining a strong position in the market.
Where can I learn more about Orion Corporation?
For further details about Orion Corporation, including financial updates and company announcements, you can reach out to their Investor Relations department or visit their official website.
